背景:膀胱肿瘤是一组具有不同临床行为和结果的异质性肿瘤。了解膀胱癌临床病理特征与分子生物标志物的预后意义之间的相关性对于个性化治疗策略和改善患者预后至关重要。
目的:这项前瞻性观察性研究旨在全面探讨膀胱肿瘤的临床病理相关性和预后意义。
方法:174名诊断为膀胱肿瘤的患者参与了这项研究。临床病理资料,包括人口统计信息,病史,影像学发现,和组织病理学报告,是从患者记录中收集的。使用免疫组织化学(IHC)对从经尿道切除术或活检获得的组织样本进行分子生物标记分析,荧光原位杂交(FISH),和分子谱分析技术。进行纵向随访评估以监测疾病进展,复发,和总体生存率。
结果:在174例诊断为膀胱肿瘤的患者中,患者的平均年龄为62.4岁(±8.7),这表明该研究队列主要包括老年人。大多数患者为男性(126,72.4%),反映出男性膀胱癌患病率高于女性。初步分析显示临床病理参数之间存在显著关联,分子生物标志物表达谱,膀胱肿瘤患者的临床结果。特定生物标志物如肿瘤蛋白p53(p53)的表达水平升高,Ki-67和估计的肾小球滤过率(EGFR)在晚期肿瘤分期(p<0.001)和更高的组织学分级(p<0.05)中观察到,表明其潜在的预后意义。此外,使用分子谱分析技术检测到的遗传改变,包括染色体的得失,与侵袭性疾病表型和复发风险显著相关(p<0.01)。纵向随访数据表明,与生物标志物表达水平较低的患者相比,具有升高的生物标志物表达水平或遗传改变的患者具有较差的治疗反应和较短的总体生存持续时间。
结论:本研究强调了整合临床病理参数和分子生物标志物数据对风险分层的重要性。治疗选择,膀胱肿瘤的预后评估。
BACKGROUND: Urinary bladder neoplasms constitute a heterogeneous group of tumors with diverse clinical behaviors and outcomes. Understanding the correlation between clinicopathological characteristics and the prognostic significance of molecular biomarkers in bladder cancer is vital for personalized treatment strategies and improved patient outcomes.
OBJECTIVE: This prospective observational study aimed to comprehensively investigate the clinicopathological correlations and prognostic significance of molecular biomarkers in urinary bladder neoplasms.
METHODS: A cohort of 174 patients diagnosed with urinary bladder neoplasm participated in this study. Clinicopathological data, including demographic information, medical history, imaging findings, and histopathological reports, were collected from the patient records. Tissue samples obtained from transurethral resection or biopsy were subjected to molecular biomarker analysis using immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and molecular profiling techniques. Longitudinal follow-up assessments were conducted to monitor disease progression, recurrence, and overall survival.
RESULTS: Out of 174 patients diagnosed with bladder neoplasms, the mean age of the patients was 62.4 years (±8.7), indicating that the study cohort primarily comprised elderly individuals. The majority of patients were male (126, 72.4%), reflecting the higher prevalence of bladder cancer among men compared to women. Preliminary analysis revealed significant associations between clinicopathological parameters, molecular biomarker expression profiles, and clinical outcomes in patients with urinary bladder neoplasms. Elevated expression levels of specific biomarkers such as tumor protein p53 (p53), Ki-67, and estimated glomerular filtration rate (EGFR) were observed in advanced tumor stages (p < 0.001) and higher histological grades (p < 0.05), indicating their potential prognostic significance. Furthermore, genetic alterations detected using molecular profiling techniques, including chromosomal gains and losses, were significantly correlated with aggressive disease phenotypes and increased recurrence risk (p < 0.01). Longitudinal follow-up data demonstrated that patients with elevated biomarker expression levels or genetic alterations had poorer treatment responses and shorter overall survival durations than those with lower biomarker expression levels.
CONCLUSIONS: This study highlights the importance of integrating clinicopathological parameters and molecular biomarker data for the risk stratification, treatment selection, and prognostic assessment of urinary bladder neoplasms.